A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.

A total of 458 eligible patients, from 21 centres, with histologically or cytologically confirmed SCLC were allocated at random to three chemotherapy regimens, each given at 3-week intervals. In two regimens, etoposide, cyclophosphamide, methotrexate and vincristine were given for a total of either...

Descripción completa

Detalles Bibliográficos
Autores principales: Bleehen, N. M., Girling, D. J., Machin, D., Stephens, R. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968636/
https://www.ncbi.nlm.nih.gov/pubmed/8260367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968636/
https://www.ncbi.nlm.nih.gov/pubmed/8260367

Ejemplares similares